Navigation Links
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
Date:9/28/2008

or ThromboGenics' shareholders."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information ple
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
3. Clinton Global Initiative Announces BDs Commitment to Biamba Marie Mutombo Hospital
4. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
5. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Phosphagenics Announces Initiation of Phase 1 Clinical Trial in Humans for Its Transdermal Lidocaine
9. Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
10. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Apr. 17, 2015 Research and Markets ... "Medical Equipment Rental and Leasing - Global Strategic ... This report analyzes the worldwide markets for Medical Equipment ... separate comprehensive analytics for the US, Japan ... of World. Annual estimates and forecasts are ...
(Date:4/17/2015)... ASSESS shows   plasma circulating ... viable alternative to tumour biopsy   IGNITE ... advanced NSCLC   AstraZeneca today presented results from ... DNA (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation ... cancer (NSCLC) in clinical practice. [ 1 ] ...
(Date:4/17/2015)... DETROIT , April 17, 2015  In Detroit, ... the infant mortality rate is two and one half times ... births. Nearly 6 of 10 infants that die in ... These are sobering statistics that Covenant Community Care, a faith-based, ... Detroit, is poised to change thanks to a charitable donation ...
Breaking Medicine Technology:Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4
... Mass., Oct. 5 Hologic, Inc. (Hologic or the ... manufacturer and supplier of premium diagnostics, medical imaging systems ... of women, today announced plans to release its fourth ... 2010 after market close. In conjunction with the release, ...
... NEW YORK, Oct. 5 Reportlinker.com announces that a ... Antidiabetics market forecast ... the antidiabetics market to grow to $34.8 billion in ... the leading franchise from 2012 after patent expiry of ...
Cached Medicine Technology:Hologic to Release Fourth Quarter Fiscal 2010 Operating Results on Monday, November 8, 2010 2Reportlinker Adds Antidiabetics Market Forecast 2
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part ... latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... In a turbulent world, people may find themselves in dangerous ... their first move, but some situations can be avoided if ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Alcohol and ... Dependence (NCADD) notes that drinking and driving has been ... At the same time, the link between alcohol and ... domestic abuse and violence and sexual assault, and their ... to the NCADD, 5.3 million adults in America were ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive ... Wednesday April 15th, the European Parliament joined its voice ... the Armenian Genocide, “paying tribute, on the eve of ... innocent Armenian victims who perished in the Ottoman Empire.” ... for this timely and needed recognition of a tragic ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 As ... above in his new offering of platelet-rich plasma ... Sports Medicine (MOSM) is known for its world-class ... Meier brings extensive surgical experience lacking in many other ... stem cell treatments are utilized for pain management and ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3
... School of Medicine investigated the role between adiponectin and ... the November issue of Hepatology , suggest that ... oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), ... Obesity is on the rise and is ...
... Dogs may not only be man,s best friend, they ... children with special needs. According to a new Universit de ... anxiety and enhance the socialization skills of children with Autism ... Psychoneuroendocrinology may be a relatively simple solution to help ...
... October 18, 2010 Neuralstem, Inc. (NYSE ... I human clinical trial of the company,s spinal cord ... Sclerosis, or Lou Gehrig,s disease) at Emory University in ... safety data from the first six non-ambulatory patients, the ...
... trial, physicians at University Hospitals (UH) Case Medical Center ... researchers are exploring the role of Vitamin D in ... along with Amitabh Chak, MD, and Gregory Cooper, MD, ... with Barrett,s esophagus to measure the effects of Vitamin ...
... Allen Institute for Brain Science have found that the ... in individuals with different genetic backgrounds. These findings may ... side-effect profiles of therapeutic drugs and thus have implications ... week,s online early edition of the Proceedings of ...
... , TUESDAY, Oct. 19 (HealthDay News) -- Monthly ... United States jumped from 4.4 percent in 2008 to 16 ... to a new survey. There was also a rise ... 0.5 percent to 1.5 percent, according to the latest National ...
Cached Medicine News:Health News:Adiponectin shows potential in blocking obesity-related carcinogenesis 2Health News:Children's best friend 2Health News:Neuralstem updates ALS clinical trial progress 2Health News:New clinical trial explores role of vitamin D in preventing esophageal cancer 2Health News:Gene activity in the brain depends on genetic background 2Health News:Online Gambling Rises Among College Males, High School Girls 2
... biopsies of soft tissue. Lightweight and compact, ... control. Precise, rapid firing mechanism provides intact ... easy penetration into the specimen with less ... of cannula helps assure an intact tissue ...
... The Bard EXPRESS Seeding Cartridge System is ... delivering radioactive seeds and spacers into a ... Each cartridge has a(n): outer radiation safety ... synthetic absorbable spacers, integrally molded fitting that ...
... very easy to use Ambulatory Urodynamic recorder ... with practising urologists as an invaluable aid ... dysfunctions. The system offers the possibility to ... a natural bladder filling, extented over a ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: